Home » Stocks » Simulations Plus

Simulations Plus, Inc. (SLP)

Stock Price: $62.84 USD -2.07 (-3.19%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed
After-hours: $62.00 -0.84 (-1.34%) Aug 11, 4:25 PM

Stock Price Chart

Key Info

Market Cap 1.23B
Revenue (ttm) 40.07M
Net Income (ttm) 9.20M
Shares Out 17.82M
EPS (ttm) 0.51
PE Ratio 123.22
Forward PE 96.15
Dividend $0.24
Dividend Yield 0.38%

Stock Quote

Trading Day Aug 11, 2020
Last Price $62.84
Previous Close $64.91
Change ($) -2.07
Change (%) -3.19%
Day's Open 64.40
Day's Range 62.58 - 65.79
Day's Volume 186,841
52-Week Range 26.00 - 73.58

More Stats

Market Cap 1.23B
Enterprise Value 1.23B
Earnings Date (est) Nov 11, 2020
Ex-Dividend Date Jul 24, 2020
Shares Outstanding 17.82M
Float 13.40M
EPS (basic) 0.53
EPS (diluted) 0.51
FCF / Share 0.45
Dividend $0.24
Dividend Yield 0.38%
Earnings Yield 0.81%
FCF Yield 0.64%
Payout Ratio n/a
Shares Short 1.78M
Short Ratio 5.66
Short % of Float 11.82%
Beta -0.08
PE Ratio 123.22
Forward PE 96.15
P/FCF Ratio 155.78
PS Ratio 30.79
PB Ratio 24.90
Revenue 40.07M
Operating Income 11.35M
Net Income 9.20M
Free Cash Flow 7.92M
Net Cash 6.34M
Net Cash / Share 0.32
Gross Margin 62.25%
Operating Margin 28.32%
Profit Margin 23.00%
FCF Margin 19.77%
ROA 14.91%
ROE 22.30%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(16.96% upside)
Current: $62.84
Target: 73.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth14.51%22.9%20.86%9.05%59.8%13.8%6.58%8.12%-18.42%-
Gross Profit24.9421.6717.8315.3713.929.838.427.947.188.17
Operating Income10.6510.308.267.235.864.444.073.613.532.87
Net Income8.588.935.794.953.843.032.893.032.712.16
Shares Outstanding17.4917.3317.2417.0316.8616.1716.0015.7615.5415.83
Earnings Per Share0.480.500.330.
EPS Growth-4%51.52%13.79%26.09%27.78%0%-5.26%11.76%30.77%-
Dividend Per Share0.
Dividend Growth0%20%0%0%5.26%-24%66.67%---
Operating Cash Flow11.649.296.885.427.145.312.563.783.502.91
Capital Expenditures-1.96-2.33-1.56-1.23-1.24-3.89-1.18-1.07-0.82-0.94
Free Cash Flow9.686.965.324.185.901.411.382.722.681.97
Cash & Equivalents11.449.406.228.038.558.6110.1812.7010.189.63
Net Cash / Debt11.449.406.228.038.558.6110.1812.7010.189.63
Book Value37.6831.9225.8022.7319.5315.4414.2415.1414.0413.05
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Simulations Plus, Inc.
Country United States
Employees 107
CEO Shawn M. O'Connor

Stock Information

Ticker Symbol SLP
Stock Exchange NASDAQ
Sector Healthcare
Industry Health Information Services
Unique Identifier NASDAQ: SLP
IPO Date June 18, 1997


Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a standalone program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for NCA and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher. In addition, it offers MedChem Studio, a software tool for data mining and designing new molecules; KIWI, a cloud-based Web application to organize, process, maintain, and communicate the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; NAFLDsym, a simulation program for analyzing nonalcoholic fatty liver disease; and RENAsym for investigating and predicting drug-induced or acute kidney injury. Further, the company provides population modeling and simulation contract research services for the pharmaceutical and biotechnology industries; and clinical-pharmacology-based consulting services in support of regulatory submissions. It sells its pharmaceutical/chemistry software to pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies. The company was founded in 1996 and is headquartered in Lancaster, California.